English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, April 2, 2018
Eisai Submits Supplemental New Drug Application to U.S. FDA
エーザイ、抗てんかん剤「Fycompa(R)」について米国で小児てんかんに係る適応で承認申請を提出
Friday, March 30, 2018
エーザイ、B型ボツリヌス毒素製剤「Neurobloc(R)」の欧州における権利をSloan Pharma社に譲渡
Wednesday, March 28, 2018
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
エーザイ株式会社と日医工株式会社の戦略提携に関するお知らせ
Friday, March 23, 2018
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」について更なる適応追加として既存治療で効果不十分な膿疱性乾癬に係る承認を取得
エーザイと米メルク、マルチキナーゼ阻害剤「レンビマ」が日本で「切除不能な肝細胞癌」の効能・効果追加の承認を取得
Wednesday, March 14, 2018
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575